Lymphoma News

SALT LAKE CITY — Patients with relapsed or refractory large B-cell lymphoma who failed chimeric antigen receptor T-cell therapy achieved durable responses with allogeneic hematopoietic stem cell transplantation, according to study results.

The FDA granted fast track designation to ADI-001 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

The FDA Oncologic Drugs Advisory Committee voted Thursday in favor of randomized data to support future approvals of phosphatidylinositol-3-kinase inhibitors, which are being developed for patients with hematologic malignancies.

The diagnosis, treatment, and long-term monitoring of patients with autoinflammatory type 1 interferonopathies require a multidisciplinary approach, according to joint guidelines released by EULAR and the American College of Rheumatology.

Infection mitigation with vaccines is essential for patients with hematologic malignancies because they are at increased risk for severe infection, hospitalization and mortality if they contract COVID-19.

There are many frustrating aspects to a cancer diagnosis.

CoVac-1, a COVID-19 vaccine, induced T-cell responses in patients with B-cell deficiencies, including those with lymphoma and leukemia, according to study results presented during American Association for Cancer Research Annual Meeting.

Natural killer cells combined with a bispecific antibody induced response among nearly 90% of patients with relapsed or refractory CD30-positive lymphoma, according to phase 1/phase 2 trial results.

Early phase 1 trial results using an investigational chimeric antigen receptor T-cell therapy manufactured at University of Colorado show encouraging efficacy for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.

The FDA approved axicabtagene ciloleucel as second-line treatment for adults with large B-cell lymphoma who are refractory to first-line chemoimmunotherapy or experienced disease relapse within 12 months of initial treatment.